Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation

Thrombosis and Haemostasis

Volumn 93, Issue 3, 2005, Pages 554-558

  Reiter, Rosemarie A ^a   Varadi, Katalin ^b   Turecek, Peter L ^b   Jilma, Bernd ^a   Knöbl, Paul ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BAXTER BIOSCIENCE   (Austria)

Author keywords

ADAMTS13; Endotoxin; Systemic inflammation; von Willebrand factor

Indexed keywords

COLLAGEN; DESMOPRESSIN; ENDOTOXIN; PLACEBO; PLASMA PROTEIN; POLYMER; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BINDING; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFUSION; MALE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN SECRETION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT; TIME; VOLUNTEER;

ACUTE DISEASE; ADAM PROTEINS; ADULT; DOUBLE-BLIND METHOD; ENDOTOXINS; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; NEUTROPHILS; PLACEBOS; PLATELET COUNT; THROMBOPHILIA; VON WILLEBRAND FACTOR;

EID: 15344341949     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-08-0467     Document Type: Article

References (29)

1. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996; 72: 341-448.
2. Dong J, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
4. Reiter RA, et al. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 1101: 946-8.
5. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
6. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
7. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
8. Martich GD, et al. Response of man to endotoxin. Immunobiology 1993; 187: 403-16.
9. Homoncik M, Blann AD, Hollenstein U, et al. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 1250-2.
10. Gralnick HR, McKeown LP, Wilson OM, et al. Von Willebrand factor release induced by endotoxin. J Lab Clin Med 1989; 113: 118-22.
11. Hollenstein U, Homoncik M, Knöbl P, et al. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans. Clin Pharmacol Ther 2002; 71: 368-74.
12. Pernerstorfer T, Hollenstein U, Hansen JB, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95: 1729-34.
13. Gerritsen A, Turecek PL, Schwarz HP, et al. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded VWF. Thromb Haemost 1999; 82: 1386-9.
14. Turecek PL, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997; 90: 3555-67.
15. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 4: 15-24.
16. Turecek PL, Pichler L, Auer W, et al. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease. Blood 1999; 94: 1637-47.
17. Suffredini AF, et al. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179: 1278-82.
18. Levi M, van der Poll T, ten Cate H, et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997; 27: 3-9.
19. Derhaschnig U, Reiter R, Knöbl P, et al. Recombinant human activated protein C (rhAPC, drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102: 2093-8.
20. Pottinger BE, Read RC, Paleolog EM, et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-94.
21. Reiter R, Derhaschnig U, Spiel A, et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003; 90: 898-903.
22. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J 2004; 147: 697-703.
23. Mannucci PM, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2002; 98: 2730-5.
24. Mannucci PM, et al. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004; 126: 213-8.
25. Crawley JTB, Lam JK, Rance JB, et al. Proteiolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105; 1085-93.
26. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-6.
27. Newby DE, et al. Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease role of interleukin-6. Thromb Haemost 1999; 81: 613-7.
28. Stohlawetz P, Folman CC, von dem Borne AEGK, et al. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81: 613-7.
29. Knöbl P, Haas M, Laczika K, et al. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: Kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003; 1: 187-9.